Latest signal
last curated pass Oct 21, 2026 · 8 public entries · source-aware summaries from 6 legacy curated cards plus llm-wiki tweets
Recent curated signals
Rx safety “Your peptides may be coming [from] fentanyl suppliers”: Johnson relays a fully verifiable gray-market peptide safety warning — TRM’s vendor-overlap numbers, CBP’s master-carton seizures, and the first reported bootleg-retatrutide deaths Johnson relayed the feed’s first full consumer-protection warning about the gray-market peptide supply chain: “Your peptides may be coming fentanyl suppliers. Anhui Renchen Technology was indicted in 2023 for supplying the Sinaloa Cartel with fentanyl precursors. Their website currently sells semaglutide and melanotan II. Of roughly 200 Chinese firms TRM Labs tracked selling fentanyl precursors, at least 50 now sell peptides. The shipments enter the US in ‘master cartons’ mislabelled as snack food, broken up by a domestic handler and mailed on. CBP has intercepted around 400 of those operations and seized over 130,000 vials in the past year. FDA records surfaced showing two deaths, one in July and one in September, reported after people injected untested black market retatrutide.” (587 likes, 93 replies, 46 reposts; October 21, 21:48 UTC). Every checkable figure verifies against the underlying record: TRM Labs’ October 6 blockchain analysis identified 150+ Chinese chemical manufacturers accepting cryptocurrency with roughly 75% listing both peptides and fentanyl precursors, and crypto inflows to those dual-listing vendors rising from $28.2 million (2023) to $33.8 million (2024) to $37.3 million (2025) with about 57% of identifiable value from the United States; the “roughly 200 firms / at least 50 now sell peptides” framing is the Wall Street Journal’s count from TRM’s longer fentanyl-precursor tracker; Anhui Rencheng (ARTC) was charged by the DOJ in June 2023 and its site still listed semaglutide and Melanotan II alongside fentanyl-class chemicals as of September 2026; CBP’s Cincinnati port had intercepted 300+ master-carton operations by March and roughly 400 by the Journal’s October count, with 2,400+ seizures and 130,000+ vials nationally from October 2025 through August 2026; and the two deaths are the July FAERS report (41-year-old woman, cardiac arrest, product from an “unreliable source”) and September report (49-year-old patient, severe dehydration, malnutrition, cardiac arrest, vial from a “research use only” site) that CBS News reported on October 13 — the first public US death reports linked to bootleg retatrutide, with causation unverified. The boundaries: TRM cannot separate peptide revenue from precursor revenue, so no individual peptide purchase is traceable to trafficking; the deaths are adverse-event reports, not established causation; retatrutide itself is an unapproved investigational drug; Johnson names no source in the post, so the numbers are his transcription; and the warning lands adjacent to his commercial position — his Immortals Pharmacy sells peptides (the GLP-1 catalog promoted in July) as the regulated alternative, which the post leaves implicit rather than disclosing. The dashboard records an attributed safety relay with verified supply-chain context—not purchasing guidance, an indictment of all peptide use, evidence that regulated alternatives are risk-free, or medical advice. 4 sourcesGray-market peptides / fentanyl-precursor vendors / retatrutide deaths Methodology “My biomarker numbers say less than people think”: Johnson endorses an unnamed paper’s critique of his own N=1 method — and pitches the aging simulation he says comes next In the feed’s most self-critical methodology post, Johnson endorsed a new paper’s argument that the foundation of his own N-of-1 — biomarkers — captures less than his audience believes: “A new paper cites my N-of-1 as a core feature of next generation longevity science. It explains why my biomarker numbers say less than people think. I agree. Aging is a multi-scale physiological process that we can’t actually measure directly. Biomarkers are like the blind men touching the elephant; able to know a piece, but never the whole. The processes that dictate aging exist at multiple levels of biological complexity… Aging manifests differently among people, but in highly nuanced and often invisible ways. The static, cross-sectional measures the field is used to can only get us so far. N-of-1 initiatives like mine can capture some of this nuance, but ultimately fails at generalizability. The authors also critique N-of-1 as able to show ‘responsiveness but not durability; optimisation but not causality.’ The challenge, so far unmet, is modelling the complexity of aging in such a way that the output is not a forecast of biomarkers, but a simulation of aging system dynamics, i.e. one’s health trajectory into the future… A choose your own adventure where we can predict the consequences of both our healthy and unhealthy behaviors. This is exactly what we are aiming to build. If you’re into this as well, hit me up.” (317 likes, 52 replies, 14 reposts; October 21, 02:40 UTC). The epistemics are sound and echo the field’s own frameworks — a Cell framework review holds that no aging biomarker yet satisfies surrogate-endpoint validation, and even the strongest responsiveness work (the TranslAGE database of 51 interventional studies) tests whether biomarkers move under intervention, not whether moving them changes health outcomes. The boundaries: the paper is not identified in the post and is not linked, so the quoted critique — including “responsiveness but not durability; optimisation but not causality” — is his transcription of an unnamed source; “the static, cross-sectional measures the field is used to” understates a field that also runs longitudinal cohorts; and the closing pivot converts the limitation into a recruitment pitch for an aging-system-dynamics simulation that exists so far as stated intent — no model, publication, team, or validation is disclosed. The dashboard records an attributed epistemic-boundary endorsement with unverified source identity—not evidence that biomarker tracking is useless, a disclosed research program, or medical advice. 3 sourcesN-of-1 limits / biomarker epistemics / aging-system simulation Rx claim “Rapamycin was the undisputed king of longevity drugs”: Johnson revisits his break-ranks decision two years on — and the skepticism he cites is now genuinely in the peer-reviewed literature Johnson posted a retrospective on his most consequential drug reversal: “Rapamycin was the undisputed king of longevity drugs. I broke ranks and stopped taking it because my extensive biomarker data showed a mixed story. Cool to see two years later that skepticism is in the peer-reviewed literature,” attaching a paper screenshot (360 likes, 42 replies, 7 reposts). His side of the record verifies on his own Blueprint essay “I stopped taking rapamycin”: the September 28, 2024 decision ended almost five years of dosing (weekly 5/6/10 mg, biweekly 13 mg, alternating 6/13 mg), taken because benefits “do not justify the hefty side-effects” he lists as intermittent skin/soft-tissue infections, lipid abnormalities, glucose elevations, and increased resting heart rate — the “mixed story” — with a then-new preprint also reporting rapamycin increased biological age on 2 of 16 epigenetic clocks. The peer-reviewed-skepticism claim verifies in direction across three published reviews: the Lancet Healthy Longevity systematic review of 19 studies found improved immune, cardiovascular, and integumentary parameters but no significant endocrine, muscular, or neurological effects, with increased infections and cholesterol/triglycerides in aging-related-disease groups; Frontiers in Aging (2025) concludes translational efficacy in humans “remains unclear,” partly for lack of standardized pharmacodynamic biomarkers; and Aging (2024) finds human data “have yet to establish that rapamycin… is a proven seno-therapeutic,” noting Kraig et al. 2018’s increases in triglycerides, HbA1c, and VLDL. The boundaries: the attached screenshot is not identified in the capture, so which specific paper he means is unrecorded; the reviews span 2023–2025, so some skepticism predates his stop rather than following it; “undisputed king” is his gloss on mouse lifespan data (ITP trials) whose human translation is exactly what the reviews question; and his discontinuation was an N=1 biomarker decision — the literature counsels uncertainty and monitoring, not that healthy adults should stop or start rapamycin. The dashboard records an attributed course-correction claim with verified literature context—not deprescribing guidance, a validation of his biomarker-driven method, or medical advice. 5 sourcesRapamycin / N=1 deprescribing / peer-reviewed skepticism Rx claim “I don’t see compelling evidence of a meaningful advantage”: Johnson turns a Phase 3 hair-loss readout into competitive positioning for his own pharmacy Quote-posting Polymarket’s announcement of Veradermics’ topline (“experimental hair-loss pill significantly increased hair growth in over 500 men, with no serious side effects,” 15,480 likes on the quoted post), Johnson ran the numbers against his own product line: “At 17 mg/day (8.5 mg twice daily), the reported increase was 36.4 hairs/cm². Conventional oral minoxidil at just 5 mg once daily achieved 35.9 hairs/cm² in a smaller published study. I don’t see compelling evidence of a meaningful advantage over normal release oral minoxidil, which is available now at my Immortals Pharmacy. I personally take 3.5 mg daily.” (2,677 likes, 140 replies, 41 reposts). Both figures are quoted accurately. Veradermics’ October 19 Phase 3 ‘304’ topline — 536 men with mild-to-moderate pattern hair loss, 8.5 mg extended-release minoxidil once or twice daily vs placebo — reported non-vellus target-area hair-count increases of 28.6 (QD) and 36.4 (BID) hairs/cm² vs 6.6 for placebo at month 6 (p<0.0001), with no treatment-related serious adverse events and no cardiac adverse events of special interest; 8.5 mg BID is the “17 mg/day” Johnson cites. The 35.9 hairs/cm² comparator traces to Panchaprateep and Luengarun’s open-label study of 30 men on 5 mg once daily for 24 weeks (+35.9 non-vellus hairs/cm², +23.6%) — the only published 5-mg hair-density dataset, as a JAMA Dermatology trial noted when citing it. The boundaries: the comparison is cross-trial, not head-to-head — a 536-person placebo-controlled Phase 3 using digital image analysis against a 30-person single-arm open-label study using manual dermoscopic counts, with different populations, doses (17 mg vs 5 mg), and formulations (extended-release vs immediate-release); near-equal topline counts across those designs are exactly the kind of comparison methodologists flag, and the Phase 3’s own co-primary patient-reported and investigator-rated endpoints have no comparator in the older study. The commercial move is the story’s second half: the post converts a would-be competitor’s topline — for a drug that is not yet FDA-approved — into a pitch for Immortals Pharmacy, while low-dose oral minoxidil is itself off-label prescribing territory requiring clinician oversight, and his personal 3.5 mg dose is an N=1 protocol claim. The dashboard records an attributed research-relay with accurately quoted numbers inside a competitive commercial frame—not a hair-loss treatment recommendation, evidence of equivalence between the two drugs, or medical advice. 4 sourcesOral minoxidil / VDPHL01 Phase 3 / Immortals Pharmacy positioning Measurement “What it takes to power my longevity home for 1 day”: the protocol publishes its first energy ledger — 52 kWh/day for the longevity stack, 93 kWh/day for the whole house, against a ~29 kWh/day average US household Johnson published the feed’s first full accounting of the physical infrastructure behind the protocol: “What it takes to power my longevity home for 1 day” — 15 kWh for the 200°F sauna, 15 kWh for evening AC holding sleep temperature at 67°F, 10 kWh for five air purifiers, 3 kWh for the Eight Sleep bed, 2 kWh each for HBOT, daylight devices, and red light therapy, and 1 kWh each for “kate’s night time erection device,” reverse-osmosis water, and IHHT — totaling “52 kWh for longevity” inside “93 kWh for whole house,” with “64 kWh solar generation” and “33 kWh exported to the grid,” closing with “A kWh is about 80 full phone charges / So about 4,200 phone charges to power my longevity protocol each day” (295 likes, 59 replies, 2 reposts). The arithmetic verifies: the ten device line items sum to exactly 52 kWh, and 52 × 80 = 4,160 ≈ “about 4,200.” The context the post leaves out: per US Energy Information Administration data the average US household consumes about 10,500 kWh of electricity per year — roughly 29 kWh per day — so the whole-house figure runs about 3.2× an average household and the longevity stack alone (52 kWh/day ≈ 18,980 kWh/yr) draws about 1.8× an average American home’s entire electricity use; and the posted solar arithmetic (64 generated − 33 exported = 31 kWh self-consumed) does not cover the 52 kWh longevity demand that day. The boundaries: all figures are self-reported for a single October day with no measurement methodology; the load is season- and home-dependent (an October evening AC line item, with sauna + AC + purifiers alone accounting for 40 of the 52 kWh); “80 phone charges per kWh” assumes a ~12.5 Wh battery, roughly half or less of current flagship phones, which would halve the phone-charge rendering; and an energy footprint is an infrastructure disclosure, not a health outcome — the post implies nothing about whether any listed device affects longevity. The dashboard records an attributed infrastructure disclosure with verified consumption context—not an efficiency standard readers should copy, evidence the devices improve health, or medical advice. 3 sourcesEnergy footprint / home protocol infrastructure / solar Female health “you’re welcome”: Johnson implies his endometriosis campaign influenced the new women’s-health executive order — the order verifies in full, the influence claim does not Just under four hours after a third-party post announced “a landmark executive order for women’s health, creating a brand-new Women’s Health Division at the National Institutes of Health” — listing endometriosis among the targeted conditions — Johnson quote-posted it with a two-word implied-credit claim: “you’re welcome” (3,624 likes, 71 replies, 53 reposts). The executive order itself verifies in full: “Advancing Women’s Health to Improve Outcomes in All Phases of Life,” signed October 19, 2026, establishes a Women’s Health Division within NIH within 90 days and a White House Women’s Health Task Force co-chaired by the Secretary of Health and Human Services and the White House Chief of Staff, with Section 1 naming endometriosis among the conditions needing more research; HHS’s release credits First Lady Melania Trump’s advocacy and notes the order revokes the prior administration’s EO 14120 (March 2024) and November 2023 memorandum. What does not verify: any connection between Johnson’s year of endometriosis posting — the July diagnosis posts, the September 23 cure-attempt announcement, the October 18 organoid method disclosure — and the order itself. No White House or HHS material mentions Johnson or his campaign, and the documented driver is the First Lady’s initiative; the implied credit is his attribution, posted hours after the news broke. The boundaries: the dashboard tracks policy relevant to the endometriosis program as context, not validation — the order is a research-coordination directive (a new NIH division, a task force, revoked prior initiatives), not a treatment change, funding guarantee, or acknowledgment of any private campaign; engagement figures were read at curation time. The dashboard records an attributed implied-credit claim with verified executive-order context—not evidence of influence, a policy endorsement, or medical advice. 3 sourcesEndometriosis / federal policy / implied credit Female health “Collected Kate’s period blood yesterday”: the endometriosis cure program discloses its first method — menstrual-blood organoids plus single-cell profiling The September 23 cure-attempt announcement acquired its first disclosed method: “Collected Kate’s period blood yesterday. 30 mL to build an organoid for her endometriosis. 30mL for single cell molecular characterization of her endometriosis.” (1,559 likes, 141 replies, 37 reposts), with a follow-up explaining the model: “An organoid allows us to recreate her biology in a lab dish so that we can model out her disease and can test potential therapies. The deep molecular profiling will be additive to our clarity of what exactly is happening now and in response to therapies.” (202 likes, 8 replies). The science is real and directly on point: Turco et al. (Communications Biology, 2021, 10.1038/s42003-021-02194-y) derived endometrial organoids from menstrual flow with an 87% success rate and showed they are transcriptomically identical to paired-biopsy organoids, explicitly naming endometriosis as a target application, and Boretto et al. (Nature Cell Biology, 2019, 10.1038/s41556-019-0360-z) established patient-derived endometriosis organoids that capture disease heterogeneity and are amenable to drug screening — the exact test-therapies-in-a-dish logic the post describes. This also executes the organoid direction Immortals named as company strategy in July. The boundaries: in the published literature, menstrual-flow organoids model the eutopic (uterine) endometrium, while endometriosis-lesion organoids have been established from surgical biospecimens — whether a menstrual-flow organoid faithfully models Tolo’s lesions is precisely the unvalidated step, and no lab, partner, established line, characterization result, therapy test, or outcome is published; the 30 mL + 30 mL volumes are self-reported (typical loss is 30–40 mL per cycle against the 80 mL heavy-bleeding research threshold), a scale-up from the 7 mL collection the program logged in August. The dashboard records an attributed method disclosure with verified organoid-literature context—not evidence that a cure or therapy test exists, a collection protocol readers can follow, or medical advice. 4 sourcesEndometriosis / organoids / menstrual blood Sleep “I got 4 hr 41 min of sleep 😭”: the sleep brand’s most-public deviation — a viral “man who invented going to bed” meme, a candid wearable confession, and an off-the-record Theranos-doc interview Twenty-two hours after promising that an RHR of 41 before bed portends “a perfect night sleep,” Johnson posted the highest-engagement @bryan_johnson message in any window this dashboard has audited: “I got 4 hr 41 min of sleep 😭” (20,760 likes, 157 replies, 216 reposts; the previous tracked maximum for his own posts was 9,557) — quote-posting a viral joke from the previous night’s private screening of the Theranos documentary “You Can See Everything”: “bf complaining that the You Can See Everything screening is going past his bedtime while bryan johnson sits two rows ahead of us. sir you are in the presence of the man who invented going to bed.” (@paularambles, 12,955 likes). The joke documents from outside what the October 16 status-engineering disclosure described from the inside — the sleep brand is now legible enough that strangers know his bedtime and find its violation funny — and the confession documents the deviation the brand rarely shows: 4 hr 41 min sits below his own endorsed “6.5-7.5 hr of sleep is ideal” band and below the AASM/SRS consensus floor of 7 or more hours per night (Watson et al., 2015), on a night he chose a private screening over bedtime. He followed with deadpan recovery humor (“thank you everyone for your thoughts and prayers,” 908 likes) and a media post revealing he had interviewed Billy Evans, Elizabeth Holmes’s partner, after the screening: “I can’t say what we talked about because it was off the record. But I will say the doc is a masterpiece… I gave him every opportunity to defend himself and strike back because Fielder roughed him up, and yet, he demurred… Most entered the evening unequivocally believing Holmes is guilty and many left unsure what just happened” (1,397 likes). The film verifies: “You Can See Everything” (A24), directed by Nathan Fielder and Lance Oppenheim about Holmes and Evans, opened in US theaters October 16, 2026 — the night of the private screening. The boundaries: engagement figures drift and were read at curation time; the meme is third-party banter retained because it independently documents how the sleep brand reads in public; the 4h41m figure is a self-reported one-night wearable readout with no posted cause-and-effect analysis — one short night is not a health event, and his own framework treats sleep consistency, not any single night, as the signal; the Evans interview content is off the record, so only Johnson’s public characterization exists — his “masterpiece” verdict and the attendee reactions are his account, not film criticism this site endorses. The dashboard records an attributed consistency-deviation and public-perception cluster with verified film context—not a protocol failure verdict, a sleep recommendation, or medical advice. 5 sourcesSleep consistency / public perception / media
// Reference paths
Move from feed to dossiers
Each route keeps source trails and medical caution visible. Protocol Health
Habits, Longterm, and Don’ts for measurement loops, sleep consistency, oral care, exercise, and experimental-intervention caution.
Protocol LongevityHabits, Longterm, and Don’ts for biomarkers, healthspan basics, critiques, and low-confidence immortality claims.
Protocol NutritionHabits, Longterm, and Don’ts for plant-led meals, Blueprint products, microplastics claims, and metabolic-drug caveats.
Protocol SleepHabits, Longterm, and Don’ts for bedtime discipline, front-loading examples, and metric caution from tweet-backed sources.
Reference Concepts39 source-aware glossary entries, including concepts without dedicated wiki pages yet.
entity BlueprintBlueprint is bryan-johnson's longevity protocol, product company, and public measurement system. It began as Project Blueprint, an N=1 effort to measure Johnson's organs and biological aging, and later became a consumer
concept Blueprint ProtocolThe Blueprint Protocol is bryan-johnson's closed-loop health system: measure body state, consult scientific evidence, implement interventions, measure again, and update. Johnson treats the body as a system whose organs a
concept Don't DieDon't Die is bryan-johnson's community slogan, longevity philosophy, and civilizational frame. The official Don't Die page describes a community “united in defeating all causes of human and planetary death and building a
concept Biomarker-driven longevity protocolsA biomarker-driven longevity protocol is a health system that treats the body as a measurable control system: collect biomarkers, choose interventions, re-measure, and iterate. project-blueprint is the most visible curre
Signal MetricsInspect source velocity by range, content type, and fallback API state.